Bupivacaine

證據等級: L5

預測適應症: 10 個

Bupivacaine: From Local/Regional Anesthesia to Acrodermatitis Chronica Atrophicans

One-Sentence Summary

Bupivacaine is a long-acting amino-amide local anesthetic widely used for nerve blocks, epidural anesthesia, spinal anesthesia, and perioperative pain management. The TxGNN model predicts it may be effective for Acrodermatitis Chronica Atrophicans, however, with 0 clinical trials and 0 publications currently supporting this specific direction, the evidence base rests entirely on AI model prediction.

Quick Overview

Item	Content
Original Indication	Local and regional anesthesia (nerve block, epidural, spinal anesthesia, pain management)
Predicted New Indication	Acrodermatitis Chronica Atrophicans
TxGNN Prediction Score	99.23%
Evidence Level	L5
Market Status	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Bupivacaine is an amino-amide local anesthetic that acts by blocking voltage-gated sodium channels (Nav1.x), preventing depolarization and nerve impulse propagation. Beyond this primary mechanism, laboratory evidence shows that bupivacaine and related local anesthetics can inhibit NF-κB signaling — a central regulator of inflammatory cytokine expression — at clinically relevant concentrations. This anti-inflammatory property is the most plausible mechanistic hook that the TxGNN model may have leveraged.

Acrodermatitis chronica atrophicans (ACA) is a late-stage cutaneous manifestation of Lyme borreliosis (Borrelia burgdorferi sensu lato infection), characterized by progressive atrophic skin changes and persistent low-grade dermal inflammation. The theoretical rationale is that bupivacaine’s NF-κB inhibition could dampen the chronic inflammatory cascade seen in ACA, particularly in the post-antibiotic residual inflammation phase.

In practice, however, this mechanistic link is extremely indirect. ACA is fundamentally an infectious disease requiring systemic antibiotic therapy; its inflammation is secondary to persistent or post-infectious immune dysregulation involving pathways (Toll-like receptor activation, complement cascades) not directly targeted by sodium channel blockade. There is no published preclinical or clinical evidence supporting any local anesthetic as a therapeutic agent for Borrelia-associated skin conditions. This prediction requires in vitro validation before it can be considered a credible repurposing candidate.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score (99.23%), there is zero clinical or preclinical evidence supporting bupivacaine for acrodermatitis chronica atrophicans, and the proposed mechanistic link — NF-κB inhibition modulating Borrelia-driven chronic skin inflammation — remains highly speculative without any experimental grounding.

To proceed, the following is needed:

Retrieve detailed MOA data from DrugBank (DG002) and TFDA SmPC warnings/contraindications (DG001)
Conduct in vitro studies examining bupivacaine’s effect on Borrelia-infected dermal fibroblasts or keratinocytes
Assess whether anti-inflammatory concentrations achievable in skin tissue are consistent with safe local delivery
Review whether any existing ACA animal models could serve as a feasibility screen
Evaluate route-of-administration compatibility: topical or intradermal delivery of bupivacaine for a chronic skin indication differs substantially from its established procedural anesthetic uses
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.